A method for quantitative determination of specific IgM antibodies in plasma

By dividing the plasma into control plasma to be tested and treated, and using excessive antigen and signaling molecules for neutralization and quantification detection, the problem of non-specific binding effects in IgM antibody detection in plasma is solved, and a high-accurate specific IgM is achieved Antibody quantitative assays are particularly suitable for the detection of Alzheimer's disease-related Aβ42 IgM antibodies.

CN113063949BActive Publication Date: 2024-11-15BLOOD TRASFUSION INST CHINESE ACAD OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110310770.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-03-23
Publication Date
2024-11-15
Estimated Expiration
2041-03-23

AI Technical Summary

Technical Problem

The prior art is difficult to avoid the nonspecific binding effect when detecting IgM antibodies in plasma, resulting in poor accuracy of the detection results, especially when monitoring Alzheimer's disease-related abnormal metabolism of β-amyloid (Aβ) is lacking effective. Quantitative determination method.

Method used

By dividing the same portion of plasma into plasma to be tested and control plasma to be treated, the antibody to be tested is neutralized by excessive antigen, complex is formed and biotinylated secondary antibodies and signal molecules are used for quantification detection, reducing the impact of non-specific binding, and calculation is calculated. Specific IgM antibody content.

Benefits of technology

Quantitative determination of specific IgM antibodies that are almost unaffected by nonspecific binding is achieved, with a wide linear range, low detection limit and good repeatability, especially when detecting Aβ42 IgM antibodies, it shows excellent detection effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113063949B_ABST
    Figure CN113063949B_ABST
Patent Text Reader

Abstract

The present invention discloses a quantitative determination method of specific IgM antibodies in plasma, which belongs to the field of antibody detection. The method comprises: 1) dividing a plasma sample into two groups, as the plasma to be tested and the control plasma to be treated; 2) incubating the control plasma to be treated with an excess of antigen, neutralizing the antibodies to be tested therein, and obtaining the control plasma; 3) using the plasma to be tested and the control plasma as samples, through which they are combined with the corresponding antigens connected to the solid phase carrier, the antigen-antibody complex is combined with the IgM antibody and the signal molecule in succession, to generate quantifiable data, and subtracting the two groups of quantifiable data to obtain the detection data; 4) using the mixed plasma of 1,000 people as the standard, diluting it into different concentrations and making a standard curve according to 1) to 3); 5) substituting the detection data of the sample to be tested into the standard curve, that is, obtaining the content of specific IgM antibodies in the plasma. The determination method of the present invention can eliminate the influence of non-specific binding, and the detection result is reliable.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of antibody detection. Background Art

[0002] Alzheimer's disease (AD) is a neurodegenerative disease with an insidious onset and is the most common cause of dementia in the elderly. Most AD patients develop the disease after the age of 65, and the incidence and severity of the disease are positively correlated with the patient's age. AD is currently incurable, and there are few drugs that can slow down its progression. With the aging of the global population, the prevalence of AD is increasing year by year, which will also generate huge social public expenditures. my country is already the country with the largest elderly population in the world. As the aging level continues to increase in the next few decades, the number of AD patients will continue to increase. There are two main reasons why there are few drugs that can slow down the progression of AD: (1) AD has an insidious onset and is difficult to detect in the early stages, thus losing the "golden period" for early intervention; (2) The pathogenesis of AD is complex and has not yet been fully clarified. Although the pathogenesis of AD has not yet been clarified, research in this area has made great progress. Among the many studies on the pathogenesis of AD, the most comprehensive one is the "β-amyloid protein (Aβ) cascade hypothesis", which believes that the occurrence of AD is due to the metabolic imbalance of Aβ production and clearance in the body, which causes it to deposit in specific brain areas to form senile plaques, and further triggers tau protein hyperphosphorylation to form NFTs, ultimately leading to synaptic loss and neuronal apoptosis. In addition, although there are other hypotheses for the pathogenesis of AD, none of them denies the important role and status of Aβ in the occurrence and development of AD.

[0003] For endogenous Aβ, if it accumulates abnormally in the body, the human body will produce effective anti-Aβ antibodies to reduce the toxic effects of Aβ. Studies have shown that abnormal Aβ metabolism occurs more than 20 years earlier than the clinical symptoms of AD, so monitoring changes in Aβ is of great significance for early warning of AD. Blood sampling is relatively convenient, but the content of Aβ in the blood is very low, and it is difficult to accurately quantify it in the blood because it is combined with other components of the blood and the detection process is affected by other components. Changes in the content of Aβ antibodies can indirectly reflect whether Aβ metabolism is abnormal, especially before the clinical symptoms of AD occur. Compared with IgG antibodies, IgM polymers have a high affinity for antigens, especially when the antigen has multiple repeated epitopes. Therefore, IgM has a higher specificity for Aβ than IgG, and its prediction of abnormal Aβ metabolism is better than IgG. At present, most of the detection of anti-Aβ antibodies in plasma uses enzyme-linked immunosorbent assay, which mainly targets IgG, and there is no unified standard. The detection methods of different studies are slightly different, but the results vary greatly. The main steps are: coating Aβ antigen to capture Aβ antibodies in plasma, and then adding secondary antibodies, enzymes and substrates to react with them. The concentration of antibodies in plasma is reflected by measuring the absorbance of the substrate. In addition, most of the IgG antibody concentrations in plasma are calibrated with mouse Aβ monoclonal antibodies (IgG) as standards. This method has great limitations: first, the composition of plasma is complex, and plasma components other than Aβ antibodies will non-specifically bind to the coated Aβ, ultimately affecting the accuracy of the test; second, there are obvious differences between mouse monoclonal antibodies and human polyclonal antibodies. Aβ has non-uniform forms such as monomers and polymers, and the antibodies produced contain many polyclonal antibodies. There are problems with using mouse monoclonal antibodies to calibrate human polyclonal antibodies.

[0004] In recent years, people have realized the impact of nonspecific binding on antibody detection, and have therefore taken certain measures, including: (1) replacing / adjusting the blocking agent, incubation time, serum dilution ratio, and secondary antibody type; (2) adding detergents (such as Tween 20) to the detergent to wash away some nonspecific binding; (3) diluting the test serum and enzyme-labeled antibody with bovine serum albumin to enhance specific adsorption. However, these methods can only reduce nonspecific binding or increase specific binding to a certain extent, but they cannot avoid the impact of nonspecific binding on the test results. In addition, for the detection of specific anti-Aβ IgM antibodies, there are no finished products for mouse IgM monoclonal antibodies and human anti-Aβ IgM antibodies. If calibration is required during the detection process, standard products must be prepared, which also brings great inconvenience to the detection. Summary of the invention

[0005] The problem to be solved by the present invention is to provide a method for quantitatively determining specific IgM antibodies which is hardly affected by non-specific binding.

[0006] The technical solution of the present invention is as follows:

[0007] A method for determining specific IgM antibodies in plasma comprises the following steps:

[0008] 1) Divide the same plasma sample into two groups, namely, the test plasma and the control plasma;

[0009] 2) using an excess amount of antigen to incubate with the control plasma to be treated, completely neutralizing and removing the antibodies to be tested in the plasma, and obtaining control plasma;

[0010] 3) Using the test plasma and control plasma as samples, allowing the components in the two groups of plasma to bind to the corresponding antigens connected to the solid phase carrier to form a complex; adding a biotinylated secondary antibody to bind to the complex, and then adding a streptavidin-labeled signal molecule to indirectly connect the signal molecule to the aforementioned solid phase carrier; by detecting the signal molecule, quantifiable data is generated, and the two groups of quantifiable data are subtracted to obtain the detection data;

[0011] 4) Substituting the test data into the standard curve to calculate the content of specific IgM antibodies;

[0012] The antigen is the antigen of the antibody to be tested;

[0013] The signal molecule in step 3) is an enzyme, a chemiluminescent molecule, a fluorescent molecule or a radioactive element;

[0014] The standard curve in step 4) is prepared by diluting the plasma with known concentration or the mixed plasma of thousands of individuals of the same animal (including human) as the standard, and obtaining the test data according to steps 1) to 3), and taking the logarithm of the plasma concentration or the dilution multiple data to obtain the standard curve.

[0015] Furthermore, the enzyme in step 3) is alkaline phosphatase, and a color reaction is generated by adding a substrate of alkaline phosphatase, and the absorbance is measured to obtain quantifiable data.

[0016] Furthermore, the plasma is human plasma, and the animal in step 4) is human.

[0017] Furthermore, the antigen of the specific IgM antibody is β-amyloid protein.

[0018] Furthermore, the β-amyloid protein is Aβ 42 Oligomers.

[0019] Furthermore, the Aβ 42 The preparation method of oligomers is as follows:

[0020] Add polymerization solution to Aβ monomers and polymerize at 4°C for 48-72h;

[0021] The polymerization liquid comprises 0.005-0.015M PBS, 0.07-0.1% by mass volume of NaCl, 0.025%-0.075% by mass volume of SDS, the medium is water, and the pH is 7.0-7.4;

[0022] Preferably, the polymerization solution comprises 0.01M PBS, 0.085% by mass volume of NaCl, and 0.05% by mass volume of SDS, the medium is water, and the pH is 7.2.

[0023] Furthermore, during the incubation process of step 2), the concentration of the antigen is 50-100 μg / ml.

[0024] Furthermore, the incubation in step 2) is carried out in an environment with a pH of 7.2 to 9.6.

[0025] Furthermore, the incubation temperature in step 2) is 4°C or 37°C.

[0026] Furthermore, the incubation time of step 2) is 1 to 3 hours.

[0027] The method of the present invention has the following beneficial effects:

[0028] The method of the present invention uses the plasma incubated with excess antigen as control plasma, which can eliminate the influence of non-specific binding on the detection result.

[0029] Experiments have shown that the method of the present invention has excellent detection effect when used to detect IgM antibodies, for example, when used to detect Aβ 42 When using IgM antibody, a wider linear range (6.25%-200% relative concentration R 2 The detection limit of the assay was 0.9866, with 1,000 plasma samples diluted 40-fold as 100%), and the assay also had a low detection limit (2.07%) and good repeatability (CV value was 5.4%).

[0030] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0031] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 :Aβ 42 Control plasma markers for different forms of incubation. A, Aβ42 Oligomer incubation; B, Aβ 42 Monomer incubation.

[0033] Figure 2 :Control plasma markers at different incubation times. A, 1h incubation; B, 3h incubation.

[0034] Figure 3 : Control plasma markers after incubation at different pH values. A, pH 7.2; B, pH 8.8; C, pH 9.6.

[0035] Figure 4 :Aβ in plasma 42 IgM antibody standard curve.

[0036] Figure 5 :Conventional methods for detecting Aβ in plasma 42 IgM antibody standard curve.

[0037] Figures 1 to 5 The antibody concentration labeled 100% on the middle horizontal axis is equivalent to the antibody concentration in 1,000 plasma diluted 40 times. DETAILED DESCRIPTION

[0038] Example 1 Specific anti-Aβ in plasma 42 Quantitative determination method of oligomeric IgM antibodies

[0039] The method of the present invention comprises the steps of:

[0040] 1. Preparation of Aβ oligomers: Aβ 42 Peptide, processed (towards Aβ 42 Hexafluoroisopropanol (HFIP) was added to the peptide and evaporated to dryness in a fume hood for 5-6 hours to make it uniform Aβ 42 After the monomer, polymerization solution (0.01M PBS, 0.085% mass volume ratio of NaCl, 0.05% mass volume ratio of SDS, medium is water, pH 7.2) was added to make Aβ 42 The concentration was raised to 100 M and polymerized at 4°C for 48-72 hours (polymerization concentration 450 μg / ml).

[0041] 2. Coating: Prepared Aβ 42 The oligomers were diluted with 0.01 M phosphate buffer (pH 6.0) and added to the ELISA plate, and coated at 4°C overnight.

[0042] 3. Blocking: Pour off the liquid in the microplate, wash the plate 5 times with plate washing solution, add 200 μl / well blocking solution, block at 37°C for 3 hours.

[0043] 4. Preparation of standard plasma, test plasma and control plasma: 1,000 mixed plasmas were used as standard, and diluted 10 times, 20 times, 40 times, 80 times, 160 times, 320 times, 640 times with diluent (1.5% BSA-TBS-T), and the test plasma was diluted 20 times or 40 times. Each standard plasma and test plasma were divided into 2 equal parts, one of which was added with excess Aβ 42 Incubate the samples to completely remove antibodies from the plasma, and use this plasma as the control plasma.

[0044] It should be noted that when excess Aβ is added to plasma 42 After incubation, the resulting mixed system is still liquid and is not separated by centrifugation or filtration.

[0045] 5. Sample addition: Pour off the liquid in the microplate, wash 5 times with the plate washing solution, add 100 μl of standard plasma, test plasma and control plasma (without antibodies) of each plasma to each well, and place at 4°C overnight.

[0046] 6. Add secondary antibody: Pour away the liquid in the microplate, wash 5 times with the plate washing solution, add 100 μl of biotin-goat anti-human IgM secondary antibody diluted 2000 times with the diluent to each well, and incubate at 25°C for 3 hours.

[0047] 7. Add enzyme: Pour away the liquid in the microplate, wash five times with plate washing buffer, add 100 μl of streptomycin-AP (streptomycin labeled with alkaline phosphatase) diluted 1500 times with plate washing buffer, and incubate at 37°C for 1.5 h.

[0048] 8. Add substrate: Pour off the liquid in the microplate, wash 5 times with the plate washing solution, add 100 μl pNPP (disodium p-nitrophenyl phosphate), and incubate at room temperature for 30 min.

[0049] 9. Termination: Add 100 μl 1M NaOH and measure the absorbance at 405 nm.

[0050] 10. Calculation of results: The absorbance of the standard plasma and the single plasma was subtracted from the absorbance of the corresponding control plasma, and the subtracted standard plasma was used as the standard curve to calculate the Aβ content in the single plasma. 42 The content of IgM antibody relative to the pooled plasma of 1,000 people.

[0051] The beneficial effects of the present invention are further illustrated by experimental examples below.

[0052] Experimental Example 1 Aβ 42 Optimization of incubation conditions with plasma

[0053] The following will dilute the mixed plasma of 1,000 people to different concentrations, and then divide each concentration into 2 parts, one of which is standard plasma and the other is Aβ 42 After incubation, the plasma was used as the control for Aβ 42The incubation conditions with plasma were optimized (Aβ 42 The antibody detection step is the same as in Example 1), and the optimization effect is judged by the quality of the standard curve prepared by the final detection value of standard plasma.

[0054] Condition 1: Different Aβ 42 Types of plasma were incubated with Aβ 42 Oligomers and Aβ 42 The monomers were incubated at 37°C for 3 h in pH 8.8 buffer. The plasma was used as the control plasma to detect Aβ in plasma. 42 The IgM antibody content was calculated by subtracting the absorbance of the plasma at different dilutions from the corresponding Aβ 42 The absorbance of the co-incubated plasma is the ordinate, and the plasma Aβ 42 The antibody concentration is the horizontal axis, and the measured absorbance is shown in Table 1; the logarithm of the two is used as the marking line, see Figure 1 .

[0055] The results show that plasma and Aβ 42 Removal of Aβ upon co-incubation of oligomers 42 IgM antibody is slightly better than plasma and Aβ 42 Monomers were co-incubated.

[0056] Table 1 shows different A β4 Absorbance measured by 2 types of incubated control plasma

[0057]

[0058] Condition 2: Aβ 42 Incubate with plasma for different time periods: 20-fold, 40-fold, 80-fold, 160-fold, 320-fold, and 640-fold diluted plasma were incubated with Aβ 42 The oligomers were incubated in pH 8.8 buffer at 37°C for 1 h and 3 h. The plasma Aβ was detected using the control plasma. 42 The IgM antibody content was calculated by subtracting the absorbance of the plasma at different dilutions from the corresponding Aβ 42 The absorbance of the co-incubated plasma is the ordinate, and the plasma Aβ 42 The antibody concentration is the horizontal axis, and the measured absorbance is shown in Table 2; the logarithm of the two is used as the marking line, see Figure 2 .

[0059] The results show that plasma and Aβ 42 Aβ was removed when oligomers were co-incubated for 3 h 42 The effect of IgM antibody was significantly better than that of co-incubation for 1 h.

[0060] Table 2 Different Aβ42 The absorbance of the control plasma incubated with

[0061]

[0062] Condition 3: Aβ in different buffer conditions 42 Co-incubation with plasma: 20-fold, 40-fold, 80-fold, 160-fold diluted plasma and 100 μg / ml Aβ 42 The oligomers were incubated at 37°C for 3 h in pH 7.2, pH 8.8, and pH 9.6 buffer conditions. The oligomers were used as control plasma to detect Aβ in plasma. 42 The IgM antibody content was calculated by subtracting the absorbance of the plasma at different dilutions from the corresponding Aβ 42 The absorbance of the co-incubated plasma is the ordinate, and the plasma Aβ 42 The IgM antibody concentration is the horizontal axis, and the measured absorbance is shown in Table 3; the logarithm of the two is used as the marking line, see Figure 3 .

[0063] The results show that plasma and Aβ 42 Removal of Aβ from plasma when co-incubated with oligomers 42 The antibody effect is better than that under pH 8.8 and pH 9.6 buffer conditions.

[0064] Table 3 Aβ under different pH buffer conditions 42 The absorbance of the incubated control plasma was measured

[0065]

[0066] Standard curve: 20-fold, 40-fold, 80-fold, 160-fold, 320-fold, 640-fold diluted plasma and 100 μg / ml Aβ 42 The oligomers were incubated at 37°C for 3 h in a pH 7.2 buffer. The plasma Aβ was detected using the plasma as a control plasma. 42 The IgM antibody content was calculated by subtracting the absorbance of the plasma at different dilutions from the corresponding Aβ 42 The absorbance of the co-incubated plasma is the ordinate, and the plasma Aβ 42 The IgM antibody concentration was taken as the horizontal axis, the absorbance was measured, and the logarithm of the two was used as the standard curve. The standard curve had good linearity, R 2 is 0.9866, see Figure 4 40-fold diluted plasma was set as Aβ 42 The IgM antibody content is 100%. This method can be used to measure the Aβ content in plasma. 42 The linear range of antibody content was 6.25%-200%.

[0067] It can be seen that the Aβ42 The antibody detection method has a wide linear range and good linearity.

[0068] Experimental Example 2 Methodological Verification of the Present Invention

[0069] This experimental example conducts a methodological evaluation on the method of Example 1, as follows:

[0070] 1. Method detection limit: The blank control was measured 8 times, and the OD values ​​were 0.097, 0.102, 0.099, 0.095, 0.102, 0.097, 0.102, 0.097, and the standard deviation δ was calculated to be 0.0028. The LOD value was calculated to be 0.0146 by substituting it into the formula (LOD = 3.3*δ / standard curve slope). Then the method detection limit was calculated to be 2.07%.

[0071] 2. Repeatability of the method: A plasma sample to be tested was diluted to three different concentrations: 50 times dilution, 100 times dilution, and 200 times dilution. Each concentration was tested three times and the CV value was calculated. The results were 91.14%, 95.68%, 99.029%, 42.46%, 46.54%, 42.15%, 23.20%, 23.98%, and 23.98%, respectively. After conversion according to the dilution multiple, the values ​​were 113.92%, 119.60%, 123.79%, 106.15%, 116.36%, 105.38%, 116.00%, 119.91%, and 119.91%, with an average of 115.67% and a CV value of 5.4%.

[0072] 3. Specificity: Will be with excess Aβ 42 The 40-fold diluted plasma incubated with oligomers was used as a specificity test sample. After testing, the absorbance of this sample was 0.0001, and it was substituted into the standard curve formula lgY = 0.6832lgX-1.9248 to calculate its antibody content, and the result was 0.00091%. In fact, this sample basically does not contain Aβ after the antigen-antibody reaction 42 IgM antibody, this result is consistent with the actual situation.

[0073] Note: The above percentages are based on the Aβ in 1,000 plasma diluted 40 times 42 The antibody content (taken as 100%) was used as a reference.

[0074] It can be seen that the method of the present invention has a low detection limit and good repeatability and specificity.

[0075] Experimental Example 3 Methodological Verification of Conventional Method (No Subtraction Control)

[0076] Based on the method of Example 1, without setting control plasma, the following methodological evaluation was performed as the object:

[0077] 1. Linear range: plasma diluted 20 times, 40 times, 80 times, 160 times, 320 times, 640 times, to detect Aβ in plasma of different concentrations 42 IgM antibody content, with the absorbance measured in different dilutions of plasma as the ordinate, plasma Aβ 42 The IgM antibody concentration is the horizontal axis, and the double logarithm of the two is used as the line. Figure 5 The standard curve has good linearity, R 2 The Aβ of plasma diluted 40 times was set to 42 If the antibody content is 100%, then this method can measure the Aβ content in plasma 42 The linear range of antibody content was 6.25%-200%.

[0078] 2. Specificity: Will be with excess Aβ 42 The 40-fold diluted plasma incubated with oligomers was used as a specificity test sample. After testing, the absorbance of this sample was 0.263, and it was substituted into the standard curve formula lgY = 0.4144lgX-1.0904 to calculate its antibody content, and the result was 17.3%. In fact, this sample basically does not contain Aβ after the antigen-antibody reaction 42 IgM antibodies indicate that other substances in the plasma seriously interfere with the test, resulting in a false positive result. This method cannot accurately reflect the true Aβ in plasma. 42 IgM content.

[0079] Note: The above percentages are based on the Aβ in 1,000 plasma diluted 40 times 42 The antibody content (taken as 100%) was used as a reference.

[0080] In summary, the quantitative determination method of specific IgM antibodies in plasma of the present invention has a wide linear range, a low detection limit, good repeatability and specificity.

Claims

1. A non-diagnostic measurement of plasma Aβ 42 The method for determining specific IgM antibodies is Features: The steps include: 1) Divide the same plasma sample into two groups, as the test plasma and the control plasma to be treated; 2) Incubate the control plasma to be treated with an excess of antigen to completely neutralize and remove the antibody to be tested in the plasma to obtain control plasma, wherein the concentration of the antigen is 100 μg / ml; the incubation is performed in an environment of pH 7.2; the incubation temperature is 37°C; the incubation time is 3 hours; the antigen is the antigen of the antibody to be tested; the antigen of the specific IgM antibody is β-amyloid protein, and the β-amyloid protein is Aβ 42 Oligomers; 3) Using the test plasma and control plasma as samples, allowing the components in the two groups of plasma to bind to the corresponding antigens connected to the solid phase carrier to form a complex; adding a biotinylated secondary antibody to bind to the complex, and then adding a streptavidin-labeled signal molecule to indirectly connect the signal molecule to the aforementioned solid phase carrier; By detecting the signal molecule, quantifiable data is generated, and the two sets of quantifiable data are subtracted to obtain detection data; 4) Substitute the test data into the standard curve and calculate the content of specific IgM antibodies; The signal molecule in step 3) is an enzyme, a chemiluminescent molecule, a fluorescent molecule or a radioactive element; Step 4) The standard curve is prepared by diluting the plasma with known concentration or the mixed plasma of thousands of individuals of the same animal as the standard, and obtaining the test data according to steps 1) to 3), and taking the logarithm of the plasma concentration or the dilution multiple data to obtain the standard curve; The Aβ 42 The preparation method of oligomers is as follows: Add polymerization solution to Aβ monomers and polymerize at 4°C for 48-72 h; The polymerization liquid comprises 0.005-0.015M PBS, 0.07-0.1% by mass volume of NaCl, and 0.025%-0.075% by mass volume of SDS. The medium is water, and the pH value is 7.0-7.

4.

2. The assay method according to claim 1, Features: The enzyme in step 3) is alkaline phosphatase, and a color reaction is generated by adding a substrate of alkaline phosphatase, and the absorbance is measured to obtain quantifiable data.

3. The assay method according to claim 1, Features: The plasma is human plasma, and the animal in step 4) is human.

4. The assay method according to claim 1, Features: The polymerization solution comprises 0.01M PBS, 0.085% by mass volume of NaCl, and 0.05% by mass volume of SDS. The medium is water, and the pH value is 7.2.